



Wilson Aarhus

May 5-8 2022

Program

Program

Thursday May 5

19.00-22.00 Welcome dinner at the venue Comwell, Værkmestergade 2, DK-8000 Aarhus C

Friday May 6

Morning

9.00 Welcome *President, Peter Ott (Aarhus)*

Session I: State of the art

Chairs: Aurélie Poujois and Thomas Sandahl

9.05 Revised AASLD Guidance: What is new? *Michael Schilsky (New Haven)*

9.25 Discussant: A critical view on the 2022 AASLD Guidance *Piotr Socha (Warsaw)*

9.35 Psychiatry in Wilson Disease *Paula Zimbrea (New Haven)*

9.55 Lipid and energy metabolism in Wilson disease *Valentina Medici (Sacramento)*

10.15 Gene and cell-based therapies in WD – the current and potential landscape *Sanjeev Gupta (Bronx)*

10.35 Coffee break

Session II: Clinical

Chairs: Jussi Sipilä and Aftab Ala

11.00 Iron In WD *Tomasz Litwin (Warsaw)*

11.15 Copper impairs cellular barrier integrity in WD *Adriana Fontes (Munich)*

11.30 Surviving WD-ALF without Transplantation *Fred Askari (Ann Arbor)*

11.45 Abstract 2: Predictors of early neurological Deterioration in Wilson's Disease during six months follow up *Agnieszka Antos (Warsaw)*

12.00 Abstract 13: Neurological worsening in Wilson Disease – Clinical classification and outcome *Isabelle Mohr (Heidelberg)*

12.15 Lunch

Friday May 6

Afternoon

Session III: Basic science

Chairs: Valentina Medici and Stephen G. Kaler

13.15	Role of nuclear receptors	<i>Svetlana Lutsenko (Baltimore)</i>
13.35	Autophagy vs apoptosis in WD	<i>Roman Polishchuk (Pozzuoli)</i>
13.55	Stem cell-based disease models to study the cellular phenotype of ATP7B mutant genotype	<i>Silvia Parisi (Naples)</i>
14.15	A new treatment regiment for Wilson Disease	<i>Hans Zischka (Munich)</i>
14.35	Developments in gene therapy	<i>Pasquale Piccolo (Naples)</i>

Session IV

14.55	Poster viewing and coffee break	
-------	---------------------------------	--

Session V: Global perspectives

Chairs: Lisbeth Birk Møller and Fred Askari

16.00	Wilson Disease in China. Management and new trends	<i>XiaoPing Wang (Shanghai)</i>
16.20	Wilson Disease in Gran Canaria	<i>Antonio Tugores (Las Palmas)</i>
16.35	UK BASL Special Interest Group	<i>William Griffiths (Cambridge)</i>
16.50	Abstract 32: Systemic aav9 with a codon-optimized reduced-size human ATP7A plus subcutaneous Cu-histidinate in Menkes disease mice	<i>Stephen G. Kaler (Ohio)</i>
17.05	Abstract 8: Wilson Disease – long term follow up. Report from national reference centre in Poland	<i>Anna Czlonkowska (Warsaw)</i>
17.20	Abstract 28: Identification of potential modifier genes in Chinese patients with Wilson Disease	<i>Donghu Zhou (Beijing)</i>
17.35	End of day	
19.00	Dinner at Smedien, Værkmestergade 7, DK-8000 Aarhus C	

Saturday May 7

Morning

Session VI: Genotype-Phenotype relation

Chairs: Sihoun Hahn and Oliver Bandmann

9.15	A pilot study of proteomic-based newborn screening for Wilson disease in WA State	<i>Sihoun Hahn (Seattle)</i>
9.30	Intronic variants and Synonymous Mutations of ATP7B	<i>Albert Stättermayer (Vienna)</i>
9.45	Disease in heterozygotes?	<i>Marta Skowronska (Warsaw)</i>
10.00	Abstract 19: Deterministic genetic combinations in Wilson Disease	<i>Fikret Pikelaiti (Paris)</i>
10.15	Genotype but no phenotype – consequence?	<i>Roderick Houwen (Utrecht)</i>
10.30	Panel Discussion: The role of genetic analysis in diagnosis and treatment	
10.45	Coffee break	

Session VII: Clinical

Chairs: Peter Ott and Piotr Socha

11.15	Abstract 30: Distribution dynamics of non-ceruloplasmin bound copper after i.v. injection studied by ⁶⁴ Cu PET/CT	<i>Ditte Emilie Munk (Aarhus)</i>
11.30	Abstract 10: Profile of MicroRNAs in Plasma Associated with the diagnosis / Prognosis of Wilsons Disease	<i>Carmen Espinós (Barcelona)</i>
11.45	Late onset Wilson Disease, the French Experience	<i>Mickael Alexandre Obadia (Paris)</i>
12.00	Lunch	

Saturday May 7

Afternoon

Session VIII: Clinical and copper measurements

Chairs: Nouzha Djebrani-Oussedik and Svetlana Lutsenko

13.00	Accurate Non-Ceruloplasmin Copper: A New Method for Wilson Disease	<i>Chris Harrington (Guildford)</i>
13.15	Measurement of NCC by HPLC-ICP-MS	<i>Christian Ward-Deitrich (LGC Laboratories, Orphalan)</i>
13.30	Abstract 16: NCC using anti-ceruloplasmin	<i>Ryan Pelto (Alexion)</i>
13.45	Abstract 6+7: Performance of relative exchangeable copper for the diagnosis in children and in acute liver failure	<i>Eduardo Couchonnal (Lyon)</i>
14.00	Abstract 27: Ion Conducting Peptide-Based Nanopores as a Powerful Sensing Tool – Ultrasensitive Detection of Bioavailable Cu(II)	<i>Alesia Tietze (Gothenburg)</i>
14.15	Abstract 22: Evaluation of copper mobilization And sequestration during treatment with ALXN1840 using novel bioanalytical methods	<i>Eugene Scott Swenson (Alexion)</i>
14.30	Abstract 29: Identifying clinically stable Wilson Disease patients: Observations and lessons From the CHELATE Trial	<i>Omar Kamlin (Orphalan)</i>
14.45	Coffee break	

Session IXa: Development of the Wilson Disease Severity Profile. Part A

Chairs: Karl Weiss and Michael Schilsky

15.15	The Need for a Wilson Disease Severity Profile	<i>Peter Ott (Aarhus)</i>
15.30	What is severity of Wilson Disease from a patient perspective?	<i>Wiebke Papenthin (Patient Representative, Germany)</i>
15.45	Development of composite endpoints, and scores and profiles	<i>Ralf-Dieter Hilgers (Aachen)</i>
16.05	A framework for the development of a Wilson Disease Severity Profile	<i>Peter Ferenci (Vienna)</i>

Session IXb: Development of the Wilson Disease Severity Profile. Part B

Chairs: Fred Askari and Tomasz Litwin

16.30	Discussant: Hepatic score	<i>Aftab Ala (London)</i>
16.40	Discussant: Neurologic score	<i>Aurélia Poujois (Paris)</i>
16.50	Discussant: Psychiatric score	<i>Paula Zimbrea (New Haven)</i>
17.15	Panel discussion	
17.45	End of day	
19.00	Dinner at MALT, Thorvaldsensgade 33B, DK-8000 Aarhus C	

Sunday May 8

Morning

Session X: Monitoring

Chair: Petr Dusek and Roman Polishchuk

9.00	Neurofilaments as expression of neurological disease	<i>Oliver Bandmann (Sheffield)</i>
9.15	Abstract 23+24: Neuroimaging correlates of brain injury, copper indices and cognitive deficits in Wilson Disease	<i>Samuel Shribman (London)</i>
9.30	FABP-1 and fibroscan as a markers of fibrosis	<i>Piotr Socha (Warsaw)</i>
9.45	Monitoring treatment in children	<i>Anil Dhawan (London)</i>
10.05	Quantification of MRI changes in WD	<i>Petr Dusek (Prague)</i>
10.25	Coffee break	

Session XI: Novel treatments/trials

Chairs: Anna Czlonkowska and Anil Dhawan

11.00	Inhibition of Cu uptake by different zinc protocols. A ⁶⁴ Cu PET study	<i>Thomas Sandahl (Aarhus)</i>
11.15	Trientine. Potential in Wilson Disease	<i>Karl Weiss (Heidelberg)</i>
11.30	Substituting TETA2HCL with TETA4HCl	<i>Aurélia Poujois (Paris)</i>
11.45	Bischoleline-TTM. Potential in Wilson Disease	<i>Michael Schilsky (New Haven)</i>
12.00	Current status and unanswered questions	<i>Peter Ferenci (Vienna)</i>
12.15	Panel discussion: interpretation of clinical trials	
12.30	Closing remarks	<i>Peter Ott (Aarhus)</i>
12.35	Lunch	
13.30	Departure	